Cargando…

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling

BACKGROUND: A translational study in patients with myeloma to determine the utility of immune profiling to predict infection risk in patients with hematological malignancy was conducted. METHODS: Baseline, end of induction, and maintenance peripheral blood mononuclear cells from 40 patients were eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teh, Benjamin W., Harrison, Simon J., Allison, Cody Charles, Slavin, Monica A., Spelman, Tim, Worth, Leon J., Thursky, Karin A., Ritchie, David, Pellegrini, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633726/ https://www.ncbi.nlm.nih.gov/pubmed/29051761 http://dx.doi.org/10.3389/fimmu.2017.01247

Ejemplares similares

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital
por: Teh, Benjamin W., et al.
Publicado: (2014)

1121. Epidemiology and Risks for Infection Following Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy at an Australian Centre
por: Smibert, Olivia, et al.
Publicado: (2018)

Infection with Scedosporium apiospermum and S. prolificans, Australia
por: Cooley, Louise, et al.
Publicado: (2007)

1010. Exploring Antimicrobial Prescriptions in a National Audit of Hematology/Oncology Inpatients Compared with the General Inpatient Population: Targeted Analysis Highlights Key Areas for Targeted Intervention
por: Douglas, Abby, et al.
Publicado: (2019)

The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients
por: Trubiano, Jason A., et al.
Publicado: (2015)

Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study
por: Debureaux, Pierre-Edouard, et al.
Publicado: (2022)

Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs
por: Thursky, Karin, et al.
Publicado: (2018)

Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network
por: Trubiano, Jason A., et al.
Publicado: (2016)

Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients
por: Roy Choudhury, Samrat, et al.
Publicado: (2021)

Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia
por: Doerflinger, Marcel, et al.
Publicado: (2021)

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma
por: Cui, Jian, et al.
Publicado: (2021)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
por: Tandon, N, et al.
Publicado: (2017)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma
por: Gherardin, Nicholas A., et al.
Publicado: (2018)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Features of Immunosenescence in Women Newly Diagnosed With Breast Cancer
por: Trintinaglia, Lauren, et al.
Publicado: (2018)

Successful identification of predictive profiles for infection utilising systems‐level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma
por: Doerflinger, Marcel, et al.
Publicado: (2021)

Using process mapping to identify barriers to effective management of sepsis in a cancer hospital: lessons for successful implementation of a whole hospital pathway
por: Thursky, K, et al.
Publicado: (2014)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital
por: Worth, L J, et al.
Publicado: (2005)

Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting
por: Xie, Ouli, et al.
Publicado: (2020)

Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
por: Teh, Joanne S. K., et al.
Publicado: (2022)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells
por: Cooke, Rachel Elizabeth, et al.
Publicado: (2020)

Prophylactic Antimicrobial Prescribing in Australian Residential Aged-Care Facilities: Improvement is Required
por: Bennett, Noleen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_la7rj3gr69stgo3o72m12p6jcc